We are live on ! Find out more
DMK

David M. Knott Portfolio holdings

AUM $275M
1-Year Est. Return 59.23%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$234M
AUM Growth
+$12.8M
Cap. Flow
-$28.9M
Cap. Flow %
-12.38%
Top 10 Hldgs %
47.79%
Holding
149
New
39
Increased
14
Reduced
25
Closed
20

Top Buys

Rank Stock Value
1
AGAC.U
African Gold Acquisition Corp Units
AGAC.U
+$6.16M
2
TWLVU
Twelve Seas Investment Company II Unit
TWLVU
+$5.13M
3
GLHAU
Glass Houses Acquisition Corp. Unit
GLHAU
+$5M
4
LOKM.U
Live Oak Mobility Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-fifth of one warrant
LOKM.U
+$3.67M
5
KAIR
Kairos Acquisition Corp. Class A Ordinary Shares
KAIR
+$2.56M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$26.2M
2
DNMR
Danimer Scientific, Inc.
DNMR
+$12.2M
3
FTAI icon
FTAI Aviation
FTAI
+$5.24M
4
UPLD icon
Upland Software
UPLD
+$5.14M
5
LKQ icon
LKQ Corp
LKQ
+$4.23M

Sector Composition

Rank Sector Weight
1 Healthcare 28.38%
2 Financials 22.64%
3 Miscellaneous 13.12%
4 Materials 11.65%
5 Technology 6.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.26B
$2.5M 1.07%
51,973
+1,200
+2% +$57.7K
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
$2.47M 1.06%
272,845
+185,929
+214% +$1.5M
EIGR
28
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.45M 1.05%
9,218
-617
-6% -$194K
UTHR icon
29
United Therapeutics
UTHR
$22.1B
$2.42M 1.04%
+14,500
New +$2.42M
JPM icon
30
JPMorgan Chase
JPM
$951B
$2.35M 1.01%
15,470
-4,500
-23% -$647K
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$2.3M 0.98%
117,688
+4,981
+4% +$102K
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.13M 0.91%
198,699
+24,000
+14% +$297K
HZAC
33
DELISTED
Horizon Acquisition Corporation
HZAC
$2.08M 0.89%
210,100
– –
AB icon
34
AllianceBernstein
AB
$3.43B
$2.02M 0.86%
50,500
– –
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$2.17B
$2.01M 0.86%
154,840
-22,700
-13% -$329K
CNST
36
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.01M 0.86%
85,909
+52,909
+160% +$1.6M
MSACU
37
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
$1.97M 0.84%
+200,000
New +$2.03M
PMGM
38
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
$1.95M 0.83%
+200,000
New +$1.96M
BRPMU
39
DELISTED
B. Riley Principal 150 Merger Corp. Unit
BRPMU
$1.76M 0.75%
+175,963
New +$1.79M
BRSL
40
Brightstar Lottery PLC
BRSL
$2.11B
$1.73M 0.74%
107,500
– –
KAIRW
41
DELISTED
Kairos Acquisition Corp. Warrant
KAIRW
$1.5M 0.64%
+130,687
New +$108K
ASLN
42
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.47M 0.63%
+10,935
New +$1.39M
CHRS icon
43
Coherus Oncology
CHRS
$218M
$1.46M 0.62%
99,655
-2,000
-2% -$34K
QURE icon
44
uniQure
QURE
$3.38B
$1.41M 0.6%
41,766
+6,766
+19% +$242K
VKTX icon
45
Viking Therapeutics
VKTX
$3.75B
$1.32M 0.56%
208,102
-10,000
-5% -$70.4K
VRCA icon
46
Verrica Pharmaceuticals
VRCA
$97.7M
$1.19M 0.51%
7,842
+183
+2% +$25.3K
PMGMW
47
DELISTED
Priveterra Acquisition Corp. II Warrant to purchase Class A common stock
PMGMW
$1.15M 0.49%
+100,000
New +$73.6K
CDTX
48
DELISTED
Cidara Therapeutics
CDTX
$1.1M 0.47%
20,765
– –
VZ icon
49
Verizon
VZ
$208B
$1.03M 0.44%
17,711
-600
-3% -$33.9K
ROCRU
50
DELISTED
Roth CH Acquisition III Co. Unit
ROCRU
$1M 0.43%
+100,000
New +$1M
1
2
3 4 5

Similar funds

FA
FMA Advisory Harrisburg, Pennsylvania $268M AUM 30.8% 1-Year Est. Return
KCP
KDI Capital Partners Raleigh, North Carolina $290M AUM 26.07% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return
ISG
Investment Security Group Denver, Colorado $252M AUM 28.26% 1-Year Est. Return
TPCM
Three Peaks Capital Management Castle Rock, Colorado $301M AUM 43.39% 1-Year Est. Return
DCM
DeGreen Capital Management Scottsdale, Arizona $301M AUM 17.24% 1-Year Est. Return
MCL
MIK Capital LP New York $247M AUM 78.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

David M. Knott's Q1 2021 Portfolio in Review

As of Q1 2021, David M. Knott held 149 positions worth $234M, up 5.8% from $221M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

David M. Knott withdrew a net $28.9M in Q1 2021, closing 20 positions and reducing 25 holdings. Its most notable exit was LKQ Corp, an estimated $4.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 36% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, David M. Knott opened a new position in African Gold Acquisition Corp Units worth $6.11M.

  • David M. Knott's largest Q1 2021 buy was African Gold Acquisition Corp Units: 618,000 shares worth $6.11M.
  • David M. Knott added most to Constellation Pharmaceuticals, Inc. in Q1 2021, an estimated $1.6M increase.
  • David M. Knott's biggest Q1 2021 reduction was Ligand Pharmaceuticals, cutting an estimated $26.2M.
  • David M. Knott fully exited LKQ Corp in Q1 2021, selling an estimated $4.23M.
  • David M. Knott's ten largest holdings make up 48% of its $234M portfolio in Q1 2021.
  • David M. Knott opened 39 new positions and closed 20 in Q1 2021.
  • David M. Knott's portfolio value rose 5.8% quarter-over-quarter to $234M.

Based on David M. Knott's 13F filing for Q1 2021, filed 13 May 2021.